Adamas Pharma (ADMS) Reports Q1 Loss of $1.06/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Adamas Pharma (ADMS) Reports Q1 Loss of $1.06/Share

Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018

March 4, 2019 4:35 PM EST

EMERYVILLE, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2018, along with key priorities for 2019. 

We are excited to expand GOCOVRIs impact on Parkinsons patients with dyskinesia in 2019, after finishing 2018, our first year of commercialization, with $34 million in sales, said Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. GOCOVRIs unique potential to meaningfully reduce both dyskinesia and OFF time in patients with Parkinsons disease receiving... More